Skip to main content
Fig. 2 | Cancer Nanotechnology

Fig. 2

From: Retro-inversion follicle-stimulating hormone peptide-modified nanoparticles for delivery of PDK2 shRNA against chemoresistant ovarian cancer by switching glycolysis to oxidative phosphorylation

Fig. 2

Effects of PDK2 knockdown on the cisplatin sensitivity of ovarian cancer cells. A PDK2 protein expression in A2780 and A2780cp cells by Western blot. B PDK2 mRNA expression in A2780 and A2780cp cells by real-time PCR. Both A2780 and A2780cp cells were transfected with PDK2 shRNA or scramble shRNA. The viability of A2780 (C) and A2780cp (D) cells measured by CCK-8 assays. Cells transfected with scramble shRNA were used as controls. Both PDK2-depleted and control cells were treated with a concentration gradient of cisplatin for 24 h. The apoptosis of A2780 (E) and A2780cp (F) cells was analyzed using flow cytometry. Both PDK2-depleted and control cells were treated with 5 μg/ml cisplatin for 24 h. ***P < 0.001, **P < 0.01

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us